WASHINGTON — Real-world data show that patients who underwent combined Hydrus microstent implantation and cataract surgery had improved IOP and were on fewer medications at 12 months.
At the American Society of Cataract and Refractive Surgery meeting, Eva Liang, MD, said clinical trials have demonstrated the benefit of the Hydrus microstent (Ivantis) plus cataract surgery, but those trials can have shortcomings.
“Clinical trials are conducted with strict entry criteria and often exclude patients commonly treated in practice,” she said. “The purpose of this study is to